148 related articles for article (PubMed ID: 29969099)
1. Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
Ojha RP; MacDonald BR; Chu TC; Fasanmi EO; Moore JD; Stewart RA
Antivir Ther; 2018; 23(7):585-592. PubMed ID: 29969099
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Naggie S; Fierer DS; Hughes MD; Kim AY; Luetkemeyer A; Vu V; Roa J; Rwema S; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Marks KM; Chung RT;
Clin Infect Dis; 2019 Jul; 69(3):514-522. PubMed ID: 31220220
[TBL] [Abstract][Full Text] [Related]
6. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Osinusi A; Townsend K; Kohli A; Nelson A; Seamon C; Meissner EG; Bon D; Silk R; Gross C; Price A; Sajadi M; Sidharthan S; Sims Z; Herrmann E; Hogan J; Teferi G; Talwani R; Proschan M; Jenkins V; Kleiner DE; Wood BJ; Subramanian GM; Pang PS; McHutchison JG; Polis MA; Fauci AS; Masur H; Kottilil S
JAMA; 2015 Mar 24-31; 313(12):1232-9. PubMed ID: 25706232
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
Stewart RA; MacDonald BR; Chu TC; Moore JD; Fasanmi EO; Ojha RP
Dig Dis Sci; 2018 Dec; 63(12):3233-3240. PubMed ID: 30014226
[TBL] [Abstract][Full Text] [Related]
8. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
9. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
10. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
J Viral Hepat; 2017 Jan; 24(1):22-27. PubMed ID: 27730717
[TBL] [Abstract][Full Text] [Related]
13. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
[TBL] [Abstract][Full Text] [Related]
14. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Feld JJ; Ramji A; Shafran SD; Willems B; Marotta P; Huchet E; Vachon ML; Svarovskaia ES; Huang KC; Hyland RH; Yun C; Massetto B; Brainard DM; McHutchison JG; Tam E; Bailey R; Cooper C; Yoshida EM; Greenbloom S; Elkhashab M; Borgia S; Swain MG
Clin Infect Dis; 2017 Jul; 65(1):13-19. PubMed ID: 28535298
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Shiha G; Esmat G; Hassany M; Soliman R; Elbasiony M; Fouad R; Elsharkawy A; Hammad R; Abdel-Razek W; Zakareya T; Kersey K; Massetto B; Osinusi A; Lu S; Brainard DM; McHutchison JG; Waked I; Doss W
Gut; 2019 Apr; 68(4):721-728. PubMed ID: 29666174
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N; Reddy KR; Nelson DR; Lawitz E; Gordon SC; Schiff E; Nahass R; Ghalib R; Gitlin N; Herring R; Lalezari J; Younes ZH; Pockros PJ; Di Bisceglie AM; Arora S; Subramanian GM; Zhu Y; Dvory-Sobol H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Sulkowski M; Kwo P;
N Engl J Med; 2014 Apr; 370(16):1483-93. PubMed ID: 24725238
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]